Tag Archives: Arrowhead Pharmaceuticals

Ascendis/Novo Terminate QM Sema Agreement; Novo Cagrisema Switch Study; Dexcom Appoints COO; Arrowhead ARO-DIMER-PA Data; Elvinix/Zealand ZP3022 Licensing Agreement; Lilly Terminates Ph1 Obesity Asset; Medtronic Expands Separation from MiniMed; Tracky Launches 16-Day CGM in India

A series of cardiometabolic-related news items has been observed from Ascendis Pharma, Novo, Dexcom, Arrowhead Pharmaceuticals, Elvinix, Lilly, MiniMed, and Tracky. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Ascletis Doses First Patient in Ph3; Arrowhead ESC 2026 Investor Event; Cytokinetics ACACIA-HCM Primary Results; Amgen Repatha Sub-Analyses; Alnylam Vutrisiran Sub-Analysis; Lilly 52-Week Taltz + Tirzepatide Data

A series of cardiometabolic-related news items has been observed from Ascletis Pharma, Arrowhead Pharmaceuticals, Cytokinetics, Amgen, Alnylam, and Lilly. Below, FENIX provides highlights and insights for the respective news items, including a projected approval timeline for Ph3 oral AOM development.

This content is for Read Less members only.
Already a member? Log in here

AZ/BMS Merger to Challenge CVRM Leaders?; Novo Business Updates; Merck, Pfizer, Amgen, and Arrowhead Q2 ’26 Earnings; Ascletis Initiates Ph3 Oral GLP-1RA Program; Lilly Reta Expanded Access; Corbus CB1 Update

A series of cardiometabolic-related news items has been observed from AZ/BMS, Novo Nordisk, Merck, Pfizer, Amgen, Arrowhead Pharmaceuticals, Ascletis Pharma, Lilly, and Corbus Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items, including insights into how the rumored AZ/BMS merger may impact the future CVRM market.

This content is for Read Less members only.
Already a member? Log in here

Madrigal and Insulet Q1 ’26 Earnings

Two cardiometabolic-related news items have been observed: Madrigal Pharmaceuticals hosted its Q1 ’26 earnings call (view press release; view slides) and Insulet hosted its Q1 ’26 earnings call (view press release; view slides). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Novo Super Bowl Ad; FDA Takes Stance on Compounding; Arrowhead Q4 ’25 Earnings

Three cardiometabolic-related new items have been observed: Novo Nordisk published its Wegovy Pill Super Bowl LX commercial (view press release); Marty Makary took a stance against compounders on X (view article; view post); and Arrowhead Pharmaceuticals hosted its Q4 ’25 earnings call (view press release). Additionally, TrumpRx (view here) has been officially launched, and FENIX will conduct an in-depth analysis early next week. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

FDA Accepts AZ’s Baxdrostat NDA and MannKind’s sNDA for FUROSCIX in CHF + CKD; Medtronic Full US Launch for Abbott-Partnered CGM; Plozasiran Breakthrough Therapy Designation; New Fractyl Data; WHO Publishes GLP-1RA Guidelines

A series of cardiometabolic-related news items has been observed from AstraZeneca, MannKind, Medtronic, Arrowhead Pharmaceuticals, Fractyl Health, and the WHO. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here